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Background: Testicular cancers constitute major therapeutic challenges in resource-limited countries and still carry
poor outcomes. There is a paucity of published data regarding testicular cancer in Tanzania, and Bugando Medical
Centre in particular. This study describes the clinicopathological pattern, treatment outcome and challenges in the
management of testicular cancer in our local setting.
Methods: This was a retrospective study including all patients who had had histopathologically confirmed
testicular cancer at Bugando Medical Centre between February 2004 and January 2014.
Results: A total of 56 testicular cancer patients were enrolled in the study, representing 0.9% of all malignancies.
The median age of patients at presentation was 28 years, with a peak incidence in the 21-to-30-year age group. A
family history of testicular cancer was reported in four (5.4%) patients. A history of cryptorchidism was reported in
six (10.7%) patients. Most patients (57.1%) presented late with an advanced stage of cancer. Testicular swelling was
the main complaint in 48 (85.7%) patients. The right testis was involved in 67.9% of cases. Lymph node and distant
metastases were documented in 10 (17.9%) and 12 (21.4%) patients, respectively. Histologically, 80.4% of patients
had germ cell cancers, with seminoma accounting for 62.2% of cases. The most common surgical procedure was
inguinal orchidectomy (77.4%). Adjuvant chemotherapy and radiotherapy were used in six (11.1%) and four
(7.4%) patients, respectively. Eight (14.3%) patients died. The main predictors of mortality (P < 0.001) were patient’s
age (>65 years), late presentation (>6 months), stage of disease, and presence of metastasis at time of diagnosis. The
mean follow-up period was 22 months. At the end of five years, only 18 (37.5%) patients were available for follow-up
and the overall 5-year survival rate was 22.2%. The main predictors of 5-year survival rate (P < 0.001) were patients’ age,
stage of disease, and presence of lymph node and distant metastases.
Conclusions: Testicular cancers, though rare in our setting, still carries a poor prognosis. Late presentation, poverty,
paucity of resources and the high cost of newer imaging and treatment modalities are major challenges to
management. Better health funding and education regarding testicular self-examination is essential.
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Testicular cancer is a relatively rare tumour type, account-
ing for approximately 1% of all male cancers globally [1].
However, testicular cancer has a very distinctive age distri-
bution and in many developed countries it is the most
commonly diagnosed malignancy among men aged be-
tween 15 and 40 years [2]. In recent decades, the incidence* Correspondence: drphillipoleo@yahoo.com
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reproduction in any medium, provided the orof testicular cancer has been increasing, with a doubling
observed since the 1960s in many Western societies. Both
western and northern Europe have high age-standardized
incidence rates of 7.8 and 6.7 per 100,000 men, respect-
ively, compared with rates of 0.6 per 100,000 men in the
black population of African descent [3]. However, despite
these observed trends in incidence and geographical varia-
tions, few hypotheses exist to explain them [4].
Testicular cancers may appear at any age but tend to
occur in three distinct age groups: infants and childrenLtd. This is an Open Access article distributed under the terms of the Creative
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adults (over 60 years) [5-7]. This tumour grows rapidly
with a doubling time of 20 to 30 days and has a high risk
of metastatic spread [6-8].
Epidemiological risk factors for the development of
testicular tumours include: a history of cryptorchidism,
Klinefelter’s syndrome, a familial history of testicular tu-
mours among first-degree relatives (father or brothers),
the presence of a contralateral tumour, and infertility
[8-10]. Trauma, hormones such as diethylstilboestrol,
and non-specific mumps-associated testicular atrophy
have also been implicated as risk factors, but there are
very little data to support this [8].
Although testicular cancer can be derived from any cell
type found in the testicles, more than 95% of testicular
cancers arise from germ cells. The germ cell testicular
cancers are classified into seminoma (classic, anaplastic
and spermatocytic variants) and non-seminomatous germ
cell tumours (embryonal carcinoma, teratocarcinoma,
teratoma, choriocarcinoma and yolk sac tumours).
Non-germ cell tumours include sex cord-gonadal stromal
tumours (derived from Leydig cells or Sertoli cells) and
miscellaneous neoplasms [11,12].
Testicular cancer has become one of the most curable
solid tumours and serves as a model for multimodal treat-
ment of malignancies [13]. The treatment of testicular tu-
mours has greatly evolved from extirpative surgery only to
cisplatin-based chemotherapy, radiotherapy and retroperi-
toneal lymph node dissection. These methods have now
rendered the condition potentially curable, and there is
documentation of excellent survival figures in the developed
world [13]. However, in the developing world, for example,
in Tanzania, the treatment outcome is still poor [6-8,13-15].
Reasons for this trend include a lack of well-established
first-line medical treatment that leads to late diagnosis and
referral, and unavailability of treatment, poverty and reluc-
tance to accept chemotherapy and radiotherapy [8,13,15].
There is a paucity of information regarding testicular
cancer in Tanzania and Bugando Medical Centre in par-
ticular. This is partly due to a lack of published local
data regarding this condition and a lack of cancer regis-
tries in this region. This study was designed to describe
our experiences of the management of testicular cancer,
highlighting the clinicopathological pattern, treatment
outcome and challenges in the management of testicular
cancer in our local setting.
Methods
This was a retrospective study including all patients who
had histopathologically confirmed testicular cancer at
Bugando Medical Centre over a 10-year period between
February 2004 and January 2014.
Bugando Medical Centre is a tertiary and teaching
hospital for the Catholic University of Health and AlliedSciences, Bugando in the north-western part of the
United Republic of Tanzania. It is situated along the
shores of Lake Victoria in Mwanza City. It has 1000 beds
and serves as a referral centre for tertiary specialist care
for a catchment population of approximately 13 million
people. The hospital has a newly established oncology
department, which provides care for all patients with
histopathologically proven cancers, including testicular
cancers. However, the department does not currently
provide radiotherapy services, owing to a lack of this fa-
cility at our centre. As a result, patients requiring this
modality of treatment have to travel long distances to
receive radiotherapy at the Tanzania Tumour Centre,
which is located a considerable distance from the study
area.
The study population included all patients who had
had histopathologically confirmed testicular cancer at
our hospital during the period studied. Patients with in-
complete data were excluded from the study.
The details of patients were collected from patients’
files kept in the medical records department, surgical
wards, operating theatres and the histopathology labora-
tory. Diagnosis of testicular tumours was made on clin-
ical grounds (palpable testicular mass with or without
abdominal mass), scrotal-abdominal ultrasonography, chest
radiography, intravenous urography and estimation of
tumour markers (β-human chorionic gonadotrophin
and α-fetoprotein). Computed tomography (CT) was
not done because this facility is not available at our
centre. Clinical staging was according to the Royal
Marsden staging system (Table 1). All diagnoses were
confirmed by histopathological analysis of the opera-
tive specimens. Relevant information regarding age at
presentation, clinical presentation, investigation and
stage of disease, histological type, treatment given, dur-
ation of follow-up, special management problems and
outcome were collected using a preformed questionnaire.
Statistical data analysis
Statistical analysis was performed using the Statistical Pack-
age for Social Sciences version 17.0 for Windows (SPSS,
Chicago, IL, United States). The median (and interquartile
range) and ranges were calculated for continuous variables,
whereas proportions and frequency tables were used to
summarize categorical variables. The chi-square (χ2) test
was used to test for the significance of association between
independent (predictor) and dependent (outcome) variables
in the categorical variables. Significance was considered for
P < 0.05. Multivariate logistic regression analysis was used
to determine predictor variables that predicted the outcome.
Ethical consideration
Ethical approval to conduct the study was obtained from
the joint institutional ethic review committee of the Catholic
Table 1 Royal Marsden Hospital staging of testicular
cancer
Stage Description
I No evidence of metastasis
IM Rising concentrations of serum markers with no other
evidence of metastasis
II Abdominal node metastases
A <2 cm diameter
B 2 to 5 cm diameter
C >5 cm diameter
III Supra-diaphragmatic nodal metastasis
M Mediastinal
N Supraclavicular, cervical or axillary
O No abdominal node metastases




L2 ≥3 metastases, <2 cm diameter
L3 ≥3 metastases, one or more of which is >2 cm diameter
Stage IV subgroups include H+ (liver metastases), Br + (brain metastases),
Bo + (bone).
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Bugando Medical Centre before the commencement of
the study.
Results
During the study period, a total of 6258 malignancies were
registered. Of these, 56 (0.9%) were histopathologicallyFigure 1 Distribution of patients according to age group.confirmed cases of testicular cancer; these formed the
study population. Patients’ ages ranged from 15 to 72
years, with a median age of 28 years (interquartile range,
26 to 30 years). The modal age group at presentation was
21 to 30 years, accounting for 39.3% of cases (Figure 1). A
total of 40 (71.4%) patients were aged 40 years and youn-
ger. A family history of testicular cancer was reported in
four (5.4%) patients. A history of cryptorchidism was re-
corded in six (10.7%) patients. A previous history of tes-
ticular atrophy was reported in one (1.8%) patient.
The duration of symptoms at presentation ranged
from 2 months to 16 months, with a median duration of
8 months (interquartile range, 6 to 10 months). The ma-
jority of patients, 32 (57.1%), presented after 6 months
of the onset of symptoms, and the remaining 24 (42.9%)
presented within 6 months of onset. The median time
interval between onset of symptoms and presentation at
our centre was significantly short in patients who pre-
sented with testicular swelling associated with pain, com-
pared with those who presented with painless testicular
swelling (P = 0.002). Table 2 shows the clinical presenta-
tion of the testicular cancer patients. In all, 38 (67.9%)
patients had right-sided testicular cancer and 16 (28.5%)
had left-sided testicular cancer. Two (3.6%) patients had
bilateral testicular cancer.
Following a full history and physical examination, scrotal-
abdominal ultrasonography, chest radiography and intraven-
ous urography were done. Computed tomography was not
available, which challenged our management, as this limited
the staging of retroperitoneal nodes. In the absence of CT
imaging, we relied on abdominal ultrasonography to detect
gross retroperitoneal lymph node involvement; as a result of
Table 2 Clinical presentation of testicular cancer patients
(N = 56)
Clinical presentations Frequency Percentages
Testicular swelling 48 85.7
Scrotal heaviness 8 14.3
Scrotal pain 7 12.5
Abdominal swelling or mass 4 7.1
Primary infertility 2 3.6
Enlargement of breasts 2 3.6
Abnormal hair distribution 1 1.8
Jaundice 1 1.8
Decreased libido 1 1.8
Table 4 Tumour stage of 56 patients with testicular
cancer





Not documented 12 21.4
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which was an obvious limitation, as staging accuracy of
abdominal disease was suboptimal. Preoperative assay
of tumour markers revealed elevated α-fetoprotein and
β-human chorionic gonadotrophin levels in 2 (3.6%)
and 16 (28.6%) patients.
Histopathologically, 82.1% of the cancers were of germ
cell origin; of these, seminoma accounted for 60.9% of
cases (Table 3). The majority of patients (39.3%) pre-
sented with stage IV (Table 4). Lymph node involvement
was seen in 10 (17.9%) patients. Distant metastasis (Stage
4) was reported in 12 (21.4%) patients; this was mainly to
the lung, liver and brain.
A total of 62 surgical operations were performed on 56
patients. Of these, inguinal orchidectomy was the most
common surgical procedure, performed on 48 (77.4%) pa-
tients (Figure 2). Retroperitoneal lymph node dissection
was not performed on any of our patients as they refused
consent after being informed of the ejaculatory difficultyTable 3 Distribution of patients according to
histopathological type
Histopathological type Frequency Percentages
Germ cell tumours 46 82.1
Seminoma 28 60.9
Embryonal carcinoma 12 26.1
Teratoma 4 8.7
Yolk sac tumour 2 4.3
Sex cord or gonadal stromal tumours 4 7.1
Granulosa cell tumour 2 50
Malignant Sertoli cell tumour 1 25
Leydig cell tumour 1 25
Mixed germ cell/sex cord stromal
tumours
4 7.1
Secondary testicular tumours 2 3.6
Lymphoma 1 50
Adenocarcinoma from the prostate gland 1 50that might follow. Three patients (who had only incisional
biopsy of the tumour) died within three days of admission
and did not have any definitive treatment. Radiotherapy
and chemotherapy were indicated in 54 (96.4%) patients.
Of these, only 10 (17.9%) received these form of treatment
modalities. Out of ten patients, six (11.1%) received
chemotherapy and four (7.4%) received radiotherapy. Of
those who received chemotherapy, Cisplatin-based com-
bination chemotherapy was used in only two patients. The
other four patients who had chemotherapy received a
combination of actinomycin-D, adriamycin, cyclophospha-
mide, vincristine and vinblastin which are provided for
free by the government. In addition to radical orchidec-
tomy, one patient who had testicular lymphoma was
treated with a combination of cyclophosphamide, doxo-
rubicin, vincristine and prednisone. The other patient who
had testicular adenocarcinoma from the prostate gland
was treated by androgen deprivation therapy with bilateral
orchidectomy and stilbestrol. The four patients who re-
ceived radiotherapy had to travel long distances to receive
radiotherapy at the Tanzania Tumour Centre located a
considerable distance from the study area. Other patients
failed to receive the recommended radiotherapy because
of the prohibitive distance to the radiotherapy centres and
the costs involved.
Twelve postoperative complications were reported in
eight patients, giving a complication rate of 14.3%. Surgical
site infection was the most common post-complications,
accounting for 33.3% of complications (Table 5).
In this study, eight patients died in hospital, giving a
mortality rate of 14.3%. According to multivariate logis-
tic regression analysis, the patient’s age (>65 years), late
presentation (>6 months), stage of disease, and presence
of metastasis at the time of diagnosis were the main pre-
dictors of mortality (P < 0.001).
Follow-up of patients among survivors (48) ranged
from 3 to 60 months with a median of 22 months (inter-
quartile range, 18 to 24 months). At the end of the
follow-up period, only 18 patients (37.5% of the survi-
vors were available for follow-up and the remaining 30
(62.5%) patients were lost to follow-up. Out of 18 pa-
tients who were available for follow-up, only four pa-
tients were alive and well at the end of five years, giving
an overall 5-year survival rate of 22.2%. According to
Figure 2 Distribution of patients according to the surgical procedure performed. UWSD, underwater seal drainage.
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diagnosis (P = 0.011), stage of disease (P = 0.004), extent
of lymph node involvement (P = 0.012) and distant me-
tastasis (P = 0.004) were found to be independent pre-
dictors of overall survival.
Discussion
Testicular cancers still remain relatively rare among na-
tive African men, as demonstrated in our study, where
we had only 56 patients in a 10-year period, showing an
incidence of 5.6 cases per year. In this study, testicular
cancer accounted for 0.9% of all diagnosed malignancies
seen during the study period in our setting. This concurs
with figures of 0.5 to 2% that have been reported from
various parts of Africa [1,3,4]. There is a marked variation
in the incidence of testicular cancer worldwide, with
Western countries having a high rate compared with Af-
rica [6-8]. This high incidence in Western nations has
been noted to be rising even further [16-18]. This has






Surgical site infection 4 33.3
Scrotal abscess 2 16.7
Scrotal hematoma 2 16.7
Wound dehiscence 2 16.7
Fournier’s gangrene 1 8.3
Adhesive bowel obstruction 1 8.3diets rich in oestrogen, increasing environmental (indus-
trial) pollution and genetic factors [8,19]. The low inci-
dence observed in this study is contrary to the rising
incidence in black Americans, and may be attributed to
the low incidence of cryptorchidism (a major risk factor)
[18,20,21]. Also, patients in this study were all native
black Tanzanian Africans in poorly industrialized loca-
tions. Genetic studies were not done on our patients
with bilateral tumours, although it is believed that many
of such tumours may be hereditary in origin.
In this study, the majority of patients were in the sec-
ond and third decades of life. This is in keeping with
most previous reports from Africa [8,18], but slightly at
variance with reports that cancer of the testis affects
young men in the third and fourth decades of life [4,5].
It is possible that the earlier occurrence of testicular
cancer in this study is related to the life expectancy in
the country, rather than any special demographic feature
of testicular cancer.
A family history of testicular cancer among first-degree
relatives (father or brothers) has been reported to increase
the risk of developing testicular cancers [8,9,13,22-28].
Approximately 10% of testicular cancers appear to be gen-
etically linked [22-25,29]. In this study, a family history of
testicular cancer was reported in 5.4% of patients, suggest-
ing that genetic factors might play an important role in
the development of this disease in Tanzania. Based on this
alarming observation, we suggest that screening pro-
grammes, especially genetic screening programmes,
should be considered as a main measure for prevention
and control of testicular cancer in this part of the
world.
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lar cancer is cryptorchidism. Up to 10% of all patients
with testicular cancer have a history of cryptorchidism
[8,26,30]. Epidemiologic studies have shown that pa-
tients with cryptorchidism have a 3 to 46 fold increased
incidence of testicular cancer [8-10,30]. In this study, a
history of cryptorchidism was obtained in 10.7% of pa-
tients. This is comparable with the findings of others,
who have reported that about 10% of all testicular cancer
patients have a previous history of cryptorchidism, mak-
ing it the single most important risk factor associated
with testicular cancer.
In keeping with other studies in developing countries
[11,12,22], the majority of patients (57.1%) in this study
presented late with an advanced stage of cancer. Late
presentation in these countries is thought to be due to ig-
norance, fear of consequences, long distances to hospitals,
and strong beliefs in traditional medicine and faith-
healers. We could not establish the reasons for late pres-
entation in this study, owing to its retrospective nature.
The late presentation of cases is an area of cancer care in
our centre that requires urgent attention. Detecting pri-
mary cancer at an early stage contributes to improved
chances for successful treatment and thus for survival.
As reported by other authors [12,22], most patients
with testicular cancer in this study presented with pain-
less testicular swelling. In this study, the median time
interval between the onset of symptoms and presenta-
tion to the tertiary care hospital was significantly short
in patients who presented with testicular swelling associ-
ated with pain, as compared with those who presented
with painless testicular swelling. A painless testicular
swelling that does not interfere with normal duties and a
lack of awareness of the disease might be a factor con-
tributing to late presentation in this study, as patients
with testicular swelling associated with pain are more
likely to present early than those without pain. In agree-
ment with other studies [11,12,22], the right testis was
frequently affected in our series. Two patients in this
study had bilateral testicular cancer. We could not find
in the literature any reasons for this anatomical side
distribution.
In this study, the diagnosis of testicular tumours was
made on clinical grounds (palpable testicular mass with
or without abdominal mass), scrotal-abdominal ultrason-
ography (to assess scrotal and abdominal masses), chest
radiography (to rule out pulmonary metastases), intraven-
ous urography and estimation of tumour markers (β-human
chorionic gonadotrophin and α-fetoprotein). These tumour
markers are useful in diagnosis, initial staging, assessing re-
sponse to therapy and early detection of relapse in germ cell
cancers [31]. Computed tomography is an important im-
aging tool for assessing retroperitoneal metastatic disease. In
this study, CT was not done because it was not availableduring the study period. This challenged our management,
as it limited the staging of retroperitoneal nodes. In the ab-
sence of CT, we relied on abdominal ultrasonography to de-
tect gross retroperitoneal lymph node involvement.
Testicular cancers are known to be of germ cell origin
in more than 95% of cases and constitute the most com-
mon malignancy in men aged 18 to 35 years [32]. Semi-
noma is reported to be the most common testicular
cancer and accounts for approximately 60 to 65% of
germ cell cancers [16,21,22,31-33]. In this study, 80.4%
of the cancers were of germ cell origin, of which semi-
noma accounted for 62.2% of cases. This concurs with
Opot and Magoha [12] in Kenya, who reported germ cell
cancers in more than 89% of cases, with seminoma ac-
counting for 67.4% of cases, but at variance with Magoha
[11] in Nigeria, who reported embryonal carcinoma as the
most common germ cell cancers. Izegbu et al. [34] in
Nigeria reported yolk sac tumours as the commonest
histological subtype. We could not establish the reasons
for these histopathological differences.
In this study, the majority of patients presented late
with an advanced stage of cancer, which is in keeping
with findings of other studies in developing countries
[11,12,22,33]. These findings are at variance with what is
reported in developed countries, where most patients
present early, at an early stage of the disease [20,21].
Late presentation and advanced disease at the time of
diagnosis in most developing countries may be explained
by delay in seeking medical services, poor testicular can-
cer awareness, poor referral systems and medical ser-
vices and a lack of screening programmes for testicular
cancer.
In this study, lymph node and distant metastases at
the time of diagnosis were recorded in 17.9% and 21.4%
of cases, respectively. A similar metastatic pattern was
recorded by Izegbu et al. [34] in Nigeria. Lymph node
and distant metastases in this study may be underre-
ported, owing to a lack of CT, which is an important fa-
cility in assessing retroperitoneal and mediastinal lymph
nodes metastases; as a result many of our patients might
have been understaged.
The treatment of testicular cancer consists of radical
orchidectomy, cisplatin-based chemotherapy, radiother-
apy and retroperitoneal lymph node dissection. The
management of testicular cancer depends on clinical
stage and histological diagnosis, although the initial
treatment for most testicular tumours is orchidectomy.
In this study, 48 (77.4%) patients had radical inguinal or-
chidectomy. The inguinal approach permits high div-
ision of the spermatic cord and early control of the
vascular and lymphatic supply, as well as en-block re-
moval of the testis with all its tunics. It remains the de-
finitive procedure for pathological diagnosis and local
treatment of testicular cancer [12,22,33]. No patient had
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increases the risk of spreading cancer cells into the scro-
tum and retroperitoneal lymph node. Dissection was not
performed on any of our patients, owing to their refusal
to consent after information regarding ejaculatory diffi-
culty was given. This is a setback to effective treatment,
which can be remedied by better patient education. Con-
sent for radical orchidectomy was often given reluctantly,
as patients perceived the procedure as emasculating, and a
threat to manhood, sexuality and fertility.
In this study, only six (11.1%) patients received combin-
ation chemotherapy, although this was irregular in most
instances and only two patients received the recom-
mended cisplatin-based chemotherapy. The other four pa-
tients who received a combination of actinomycin-D,
adriamycin, cyclophosphamide, vincristine and vinblastin
defaulted and did not complete the course. This observa-
tion is in keeping with other African studies [11,12,22]. It
is not clear why cisplastin-based chemotherapy, which is
much more effective, was used in only two patients, al-
though the high cost might have been a factor. Non-
adherence to chemotherapy is a major challenge in cancer
treatment, especially in resource-poor settings like ours.
Reasons for non-adherence in most developing countries
include financial difficulty, feeling relatively well after
commencement of chemotherapy, resorting to alternative
treatment and drug side effects. We could not establish
the reasons for non-adherence to chemotherapy in our
study, owing to its retrospective nature.
Adjuvant radiotherapy is an integral part of the man-
agement of testicular cancer. In this study, only four
(7.4%) of patients requiring adjuvant radiotherapy had
access to this modality of treatment. Adjuvant radiother-
apy is required to reduce the risk of local recurrence fol-
lowing surgery [12,22,33]. Failure to access this modality
of treatment in our patients can be explained by the fact
that radiotherapy is not available at our tertiary care
hospital and therefore patients requiring this form of
treatment had to travel long distances to receive radio-
therapy elsewhere. Because of lack of funds at the time
of referral for radiotherapy in the majority of patients,
less than 10% of patients were able to travel and received
this form of treatment.
The prognosis of testicular cancer has remained poor
in most developing countries, where most patients are
already in an advanced stage of the disease at the time of
diagnosis, which has been proven both in the present
study and in most studies conducted in developing
countries [11,12,22,33]. However, when it is diagnosed
and treated early, testicular cancers are curable; a 5-year
survival rate of over 95% has been achieved in developed
countries [20,32]. The overall 5-year survival rate of
22.2% in our study is significantly lower than the survival
rate of testicular cancer patients managed in developedcountries [20,32]. The low overall 5-year survival rate in
this study can be explained by the fact that most of our
patients generally seek medical attention when the dis-
ease has reached an advanced stage. Therefore, diagnosis
is made when the chance of a full cure is low. The low
overall 5-year survival rate in this study may also be ex-
plained by the fact that cisplastin-based chemotherapy
combination was used in only two patients, probably
owing to its high cost. It is hoped that these results
will encourage surgeons in this locality to insist on
cisplastin-based combination chemotherapy for tes-
ticular cancer, irrespective of costs. In our patients, the
factors that significantly affected overall survival were
age of the patient, stage of disease, lymph node, and
distant metastases and histological type. The follow-up
of patients in this study was generally poor as more
than 60% of patients were lost to follow-up by the end
of five years.
The major limitation of this study is the fact that in-
formation about some patients was incomplete, in view
of the retrospective nature of the study. This might have
introduced some bias in our findings. The large number
of patients lost to follow-up was also a major limitation
of this study, as it means that we may have underesti-
mated the 5-year overall survival rates. Also, this study
included patients who were evaluated and treated at a
single institution, and so it might not reflect the whole
population in this region, despite the fact that approxi-
mately 70% of oncology patients in northwestern Tanzania
are managed at our centre. However, despite these limita-
tions, findings from this study provide local data that can
be utilized to improve the care of testicular cancer in our
local setting. The challenges identified in the management
of testicular cancer in our setting need to be addressed to
deliver optimal care for these patients.
Conclusions
Testicular cancer, although rare in Tanzania and Bugando
Medical Centre in particular, poses a great challenge in
the management of this disease. Late presentation,
high-stage disease at presentation, poor accessibility to
healthcare facilities, lack of diagnostic and staging fa-
cilities, absence of radiotherapy facilities in northwest-
ern Tanzania, non-adherence to adjuvant therapy, high
costs of newly recommended drugs, and lack of patient
awareness of testicular self-examination are major chal-
lenges in the care of these patients. To address these chal-
lenges, we recommend that the public receive education
regarding the importance of early presentation to health
facilities and follow-up following treatment, a significant
increase in health care funding, expansion of the health
insurance scheme to cover cancer treatment, and im-
proved patient education. The inclusion of teaching tes-
ticular self-examination in the primary and secondary
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